ClinicalTrials.gg
RecruitingNCT07444372STOP-AFibUpdated Oct 5, 2026

Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation

An interventional study of Continuous Positive Airway Pressure (CPAP) and Usual Care in Obstructive Sleep Apnea, Sleep Disorder (Disorder) and Atrial Fibrillation (AF), sponsored by Beijing Anzhen Hospital. Recruiting at 30 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Beijing Anzhen Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 5, 2026Site recruiting status changedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
658
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 108 studies in Sleep Apnea, Obstructive with a site in China — 48 open to participants now, 50 under way, 10 of them phase 3. Sleep Apnea, Obstructive · China.

Planned enrollment
4th of 60
658 · median 140
Started
2026
with 14 others
No phase
42 of 108
11 open now
Primary completion
2029-01
later than 44 of 49 live
Registered
97th of 108
by date
Lead sponsor
7 of 108
Beijing Anzhen Hospital

Among the 108 studies in Sleep Apnea, Obstructive with a site in China, this one is the 4th largest by planned enrollment of the 60 interventional ones that give a count, is one of 15 that started in 2026, is one of 42 with no phase, reaches primary completion later than 44 of the 49 other live ones, and was the 97th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

48 of the 108 studies in Sleep Apnea, Obstructive with a site in China are open now. Recruiting first, the newest first:

42 more — sign in →

All 48 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Sleep Apnea, Obstructive with a site in China, or all of them as a file.
02

Study summary

Atrial fibrillation (AF) is one of the most common clinical arrhythmias. Catheter ablation is an effective therapeutic strategy; however, recurrence rates remain substantial, ranging from 20% to 45%. Previous studies have established a strong association between obstructive sleep apnea (OSA) and the risk of AF recurrence following ablation. While continuous positive airway pressure (CPAP) is the standard intervention for OSA, and some observational studies suggest it may reduce post-ablation recurrence in patients with comorbid OSA, small randomized controlled trials have failed to confirm a clear benefit, potentially due to poor adherence.

This study aims to evaluate the clinical benefit of post-ablation CPAP therapy in AF patients with comorbid OSA.

Participants will:

  • Be randomly assigned to either the CPAP group or the usual care group.
  • If in the CPAP group, use a CPAP device for 12 months.
  • Wear an ambulatory ECG recorder for a 7-day period at 3, 6, 9, and 12 months after randomization.
  • Complete follow-up checkups either at the clinic or over the phone at 1, 3, 6, and 12 months after randomization.
Read the detailed description

Atrial fibrillation (AF) is a common sustained cardiac arrhythmia, with recurrence rates of 20-45% after catheter ablation. Obstructive sleep apnea (OSA) is a common comorbidity and an important modifiable risk factor for post-ablation AF recurrence. Continuous positive airway pressure (CPAP) is the standard therapy for OSA, but its effect on reducing AF recurrence after ablation remains uncertain.This study aims to evaluate whether, in patients with OSA and AF who undergo catheter ablation, the postoperative CPAP treatment can increase the rate of no recurrence of atrial arrhythmia within one year compared to usual treatment. This prospective, multicenter, open-label, parallel-group randomized controlled trial will be conducted at approximately 20 centers in mainland China. Approximately 658 adults aged 18-75 years with persistent AF and diagnosed OSA who have successfully undergone first-time catheter ablation will be enrolled.

After confirmation of eligibility and informed consent, participants will be randomized in a 1:1 ratio to receive either CPAP therapy plus usual care or usual care alone. CPAP therapy will be provided for 12 months, with treatment parameters determined by pressure titration, and adherence monitored using device-recorded data. Participants in the usual care group will receive standard AF management and standardized education regarding OSA; additional OSA treatments outside the study protocol will be permitted and documented.All participants will receive guideline-directed medical therapy for AF.

Follow-up will last at least 12 months, with assessments at approximately 1, 3, 6, and 12 months after randomization. Atrial arrhythmia monitoring will be performed primarily using ambulatory ECG recorders.

The primary outcome is freedom from atrial arrhythmia recurrence within 12 months after randomization. Secondary outcomes include atrial arrhythmia recurrence patterns, arrhythmia-related interventions, atrial fibrillation burden, and changes in quality-of-life and psychological assessment scores.

03

Conditions studied

  • Obstructive Sleep Apnea
  • Sleep Disorder (Disorder)
  • Atrial Fibrillation (AF)
  • Sleep Disordered Breathing (SDB)
  • Arrhythmia
  • Continuous Positive Airway Pressure

Keywords

  • Obstructive Sleep Apnea
  • Continuous Positive Airway Pressure
  • Atrial Fibrillation
  • Ablation of atrial fibrillation
  • Sleep Disordered Breathing
  • Clinical Trial
  • Catheter Ablation
04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all of the following conditions to be eligible for the study:

  • Age 18-75 years.
  • Patients with persistent AF who received catheter ablation for the first time.
  • Diagnosed with OSA.
  • Able to tolerate CPAP therapy.
  • Capable of understanding and complying with the study protocol.
  • Willing to sign the form.

Exclusion criteria

Exclusion Criteria:

Patients meeting any of the following criteria will be excluded from the study:

  • Secondary AF.
  • Left atrial anteroposterior diameter 60mm (measured via parasternal long-axis view).
  • \< 30%.
  • Comorbid moderate-to-severe mitral stenosis or history of prosthetic valve replacement (mechanical or bioprosthetic).
  • Pregnant or breastfeeding women.
  • History of myocardial infarction, percutaneous coronary intervention, or cardiac surgery within 3 months prior to screening.
  • History of stroke or within 6 months prior to screening.
  • Perioperative complications related to the ablation procedure occurring prior to randomization.
  • Inability to discontinue antiarrhythmic drugs (AADs) post-procedure due to other reasons.
  • \< 1 year.
  • Central sleep apnea.
  • Conditions requiring ventilatory support, including obesity hypoventilation syndrome (defined as > 30kg/m² and awake PaCO₂ > 45mmHg), amyotrophic lateral sclerosis, or with > 1 episode of respiratory failure or hypercapnia.
  • Treatment-emergent central sleep apnea during CPAP tolerance assessment that cannot be corrected prior to randomization.
  • Receipt of instrumental or surgical treatment for OSA within 3 months prior to screening, including CPAP, oral appliances, ENT surgery, or bariatric surgery.
  • Use of glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide receptor agonists, or glucagon receptor agonists for weight loss within 3 months prior to screening, or plans to initiate such medications within the next year.
  • Current participation in other drug or device trials.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
658 participants (estimated)

Study arms

  • Experimental
    CPAP Group

    Usual care combined with CPAP therapy.

    Device: Continuous Positive Airway Pressure (CPAP) · Other: Usual Care

  • Active comparator
    Usual Care Group

    Standard of care for atrial fibrillation and usual care for OSA (health education). Researchers advise participants to visit sleep centers or pulmonology departments for further assessment/treatment at their own discretion, but do not intervene in their choice of OSA therapy or provide the study CPAP device.

    Other: Usual Care

Interventions

  • DeviceContinuous Positive Airway Pressure (CPAP)

    Participants receive CPAP therapy provided by the research team. Treatment parameters are determined following auto-titrating or manual pressure titration. Prior to treatment initiation, participants receive training on device usage, mask fitting and adjustment, equipment cleaning and maintenance, and data transmission methods. Study physicians and technicians provide support to address any CPAP-related discomfort. 'Good adherence' is defined as device usage of ≥ 4 hours per night on ≥ 70% of days.

  • OtherUsual Care

    Participants receive standardized medical therapy for atrial fibrillation in accordance with international guidelines and clinical routine. For OSA management, researchers provide standardized health education. This includes informing participants about the risks associated with OSA and advising on lifestyle modifications, including weight loss, adopting a lateral sleeping position, and avoiding alcohol and sedatives.

06

What researchers measure

Primary outcomes

  1. Incidence of freedom from atrial arrhythmia recurrence.

    Recurrence is defined as a composite of: 1. Any documented atrial arrhythmia (AF / Atrial Tachycardia \[AT\] / Atrial Flutter \[AFL\]) lasting 30 seconds after a 3-month blanking period; 2. Use of Class I or III AADs after the 3-month blanking period; 3. Cardioversion performed after the 3-month blanking period; 4. Repeat catheter ablation performed at any time.

    Time frame: Within 12 months

Secondary outcomes

  1. Incidence of any documented atrial arrhythmia (AF/AFL/AT) lasting ≥30 seconds.

    Time frame: Within 12 months (after a 3-month blanking period).

  2. Incidence of documented AF lasting ≥30 seconds.

    Time frame: Within 12 months (after a 3-month blanking period).

  3. Incidence of documented AT lasting ≥30 seconds.

    Time frame: Within 12 months (after a 3-month blanking period).

  4. Incidence of documented AFL lasting ≥30 seconds.

    Time frame: Within 12 months (after a 3-month blanking period).

  5. Proportion of patients using Class I or III antiarrhythmic drugs.

    Time frame: Within 12 months (after a 3-month blanking period).

  6. Proportion of patients undergoing cardioversion.

    Time frame: Within 12 months (after a 3-month blanking period).

  7. Proportion of patients undergoing repeat catheter ablation.

    Time frame: Within 12 months.

  8. AF burden

    Time frame: Within 12 months.

  9. Change in quality of life assessed by the Atrial Fibrillation Effect on Quality-of-Life questionnaire.

    Scores range from 0 to 100, where higher scores indicate a better quality of life.

    Time frame: Baseline, Month 12.

  10. Change in anxiety and depression assessed by the Hospital Anxiety and Depression Scale.

    Scores for both the anxiety and depression subscales range from 0 to 21, where higher scores indicate worse anxiety and depression.

    Time frame: Baseline, Month 12.

07

Study locations

3 of 30 sites recruiting
  • Beijing Chaoyang Hospital, Capital Medical University
    Beijing, Beijing Municipality 100020, China
    Not yet recruiting
    • Zhiling Zhao, Professor · Contactcysleep@163.com · +86-10-85231000
    • Zhiling Zhao, Professor · Principal investigator
  • Beijing Anzhen Hospital
    Beijing, Beijing Municipality 100029, China
    Recruiting
    • Jiang Xie, Professor · Contactfrank782008@aliyun.com · +86 64456360
    • Jiang Xie, Professor · Principal investigator
    • Shaoping Nie, Professor · Principal investigator
    • Deyong Long, Professor · Principal investigator
  • Beijing Jishuitan Hospital
    Beijing, Beijing Municipality 100035, China
    Not yet recruiting
    • Yang Cheng, Professor · Contacthengyang0323@outlook.com · +86 01058516688
    • Yang Cheng, Professor · Principal investigator
  • Beijing Hospital
    Beijing, Beijing Municipality 100730, China
    Not yet recruiting
    • Wei Gong, Professor · Contactgongwei5180@bjhmoh.cn · +86 85132266
    • Wei Gong, Professor · Principal investigator
  • Peking University International Hospital
    Beijing, Beijing Municipality 102206, China
    Not yet recruiting
    • Yanwen Jiang, Professor · Contactjiangyanwen@pkuih.edu.cn · +86 01069006163
    • Yanwen Jiang, Professor · Principal investigator
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
    Not yet recruiting
    • Xiangqi Chen, Professor · Contactchxqq2003@126.com · +86-591-83357896
    • Xiangqi Chen, Professor · Principal investigator
  • First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350004, China
    Not yet recruiting
    • Ningfang Lian, Professor · Contact1533532863@qq.com · +86 059187981698
    • Ningfang Lian, Professor · Principal investigator
  • Zhangzhou Hospital of Fujian Province
    Zhangzhou, Fujian 363000, China
    Not yet recruiting
    • Li Lin, Professor · Contactlinlid222@163.com · +86-596-2082000
    • Li Lin, Professor · Principal investigator
  • People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530021, China
    Not yet recruiting
    • Mingming Zhao, Professor · Contacttopabigale@163.com · +86-771-2186076
    • Mingming Zhao, Professor · Principal investigator
  • Langfang People's Hospital
    Langfang, Hebei 065000, China
    Not yet recruiting
    • Zengming Xue, Professor · Contactxuezengming@163.com · +86 03162369665
    • Zengming Xue, Professor · Principal investigator
  • Shijiazhuang Great Wall Hospital of Integrated Traditional Chinese and Western Medicine
    Shijiazhuang, Hebei 050000, China
    Recruiting
    • Linyi Huang, Professor · Contact496777551@qq.com · +86-0311-85837801
    • Linyi Huang, Professor · Principal investigator
  • The Ninth Hospital of Xingtai
    Xingtai, Hebei 055250, China
    Recruiting
    • Zhanwei Liu, Professor · Contactliuzhanweidf@sina.com · +86-0319-4321827
    • Zhanwei Liu, Professor · Principal investigator
  • Second Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150086, China
    Not yet recruiting
    • Wei Meng, Professor · Contactmengweixq@163.com · +86 045186296870
    • Wei Meng, Professor · Principal investigator
  • Shangqiu First People's Hospital
    Shangqiu, Henan, China
    Not yet recruiting
    • Renshan Niu, Professor · Contactniurenshan1965@163.com · +86-0370-3255630
    • Renshan Niu, Professor · Principal investigator
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
    Not yet recruiting
    • Gangqiong Liu · Contactdoctorliu61352@163.com · +86-371-66913114
    • Gangqiong Liu, Professor · Principal investigator
  • Wuhan No. 1 Hospital
    Wuhan, Hubei 430014, China
    Not yet recruiting
    • Zhihua Yu, Professor · Contactwhyu027@163.com · +86 02785332144
    • Zhihua Yu, Professor · Principal investigator
  • Wuhan Asia General Hospital
    Wuhan, Hubei 430056, China
    Not yet recruiting
    • Ning Man, Professor · ContactMannyl75@126.com · +86-027-84788999
    • Ning Man, Professor · Principal investigator
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
    Not yet recruiting
    • Ruoyun Ouyang, Professor · Contactouyangruoyun@csu.edu.cn · +86-731-85295888
    • Ruoyun Ouyang, Professor · Principal investigator
  • The First Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210029, China
    Not yet recruiting
    • Ning Ding, Professor · Contactdingning@njmu.edu.cn · +86 02568307346
    • Ning Ding, Professor · Principal investigator
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
    Not yet recruiting
    • Haibo Yuan, Professor · Contacthyuan@jlu.edu.cn · +86-431-88782222
    • Haibo Yuan, Professor · Principal investigator
  • First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116011, China
    Not yet recruiting
    • Haiying Tang, Professor · Contactdoctortanghy@163.com · +86 0411836359632561
    • Haiying Tang, Professor · Principal investigator
  • First Affiliated Hospital of China Medical University
    Shenyang, Liaoning 110001, China
    Not yet recruiting
    • Wenyang Li, Professor · Contact20122043@cmu.edu.cn · +86 83282530
    • Wenyang Li, Professor · Principal investigator
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110004, China
    Not yet recruiting
    • Li Xiao, Professor · Contactxiaolisy@163.com · +86-24-96615
    • Li Xiao, Professor · Principal investigator
  • Shengli Oilfield Central Hospital
    Dongying, Shandong 257034, China
    Not yet recruiting
    • Xiangfei Liu, Professor · Contactzhaoyang20023903@126.com · +86-546-8551222
    • Xiangfei Liu, Professor · Principal investigator
  • Linyi People's Hospital
    Linyi, Shandong 276003, China
    Not yet recruiting
    • Li Wei, Professor · Contactweilineu@163.com · +86-539-8216261
    • Li Wei, Professor · Principal investigator
  • Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi 030001, China
    Not yet recruiting
    • Xiaoling Gao, Professor · Contactyihexiyuan@qq.com · +86 03513362858
    • Xiaoling Gao, Professor · Principal investigator
  • Tianjin Chest Hospital
    Tianjin, Tianjin Municipality 300222, China
    Not yet recruiting
    • Fang Zhao, Professor · Contactzfangdoctortjxkyy@163.com · +86-22-88185111
    • Fang Zhao, Professor · Principal investigator
  • Yan'an Hospital of Kunming City
    Kunming, Yunnan, China
    Not yet recruiting
    • Xia Jiang, Professor · Contact378972370@qq.com · +86-0871-63211073
    • Xia Jiang, Professor · Principal investigator
  • First Affiliated Hospital of Ningbo University
    Ningbo, Zhejiang 315010, China
    Not yet recruiting
    • Maoqing Tong, Professor · Contactganbaursy@163.com · +86 57487085588
    • Maoqing Tong, Professor · Principal investigator
  • Tianjin Medical University Second Hospital
    Tianjin, China
    Not yet recruiting
    • Xiaoyun Zhao, Professor · Contactzxydoctor@163.com · +86-022-88326681
    • Xiaoyun Zhao, Professor · Principal investigator
08

References and documents

Publications

  • Dretzke J, Chuchu N, Agarwal R, Herd C, Chua W, Fabritz L, Bayliss S, Kotecha D, Deeks JJ, Kirchhof P, Takwoingi Y. Predicting recurrent atrial fibrillation after catheter ablation: a systematic review of prognostic models. Europace. 2020 May 1;22(5):748-760. doi: 10.1093/europace/euaa041. PubMed 32227238 ↗
  • Sanchez-de-la-Torre M, Gracia-Lavedan E, Benitez ID, Sanchez-de-la-Torre A, Moncusi-Moix A, Torres G, Loffler K, Woodman R, Adams R, Labarca G, Dreyse J, Eulenburg C, Thunstrom E, Glantz H, Peker Y, Anderson C, McEvoy D, Barbe F. Adherence to CPAP Treatment and the Risk of Recurrent Cardiovascular Events: A Meta-Analysis. JAMA. 2023 Oct 3;330(13):1255-1265. doi: 10.1001/jama.2023.17465. PubMed 37787793 ↗
  • Caples SM, Mansukhani MP, Friedman PA, Somers VK. The impact of continuous positive airway pressure treatment on the recurrence of atrial fibrillation post cardioversion: A randomized controlled trial. Int J Cardiol. 2019 Mar 1;278:133-136. doi: 10.1016/j.ijcard.2018.11.100. Epub 2018 Nov 20. PubMed 30522886 ↗
  • Hunt TE, Traaen GM, Aakeroy L, Bendz C, Overland B, Akre H, Steinshamn S, Loennechen JP, Hegbom F, Broch K, Lie OH, Lyseggen E, Haugaa KH, Gullestad L, Anfinsen OG. Effect of continuous positive airway pressure therapy on recurrence of atrial fibrillation after pulmonary vein isolation in patients with obstructive sleep apnea: A randomized controlled trial. Heart Rhythm. 2022 Sep;19(9):1433-1441. doi: 10.1016/j.hrthm.2022.06.016. Epub 2022 Jun 16. PubMed 35716856 ↗
  • Zhou Y, Yan M, Yuan J, Wang Y, Qiao S. Continuous Positive Airway Pressure Treatment Decreases the Risk of Atrial Fibrillation Recurrence in Patients with Obstructive Sleep Apnea after Radiofrequency Ablation. Int Heart J. 2022 Jul 30;63(4):716-721. doi: 10.1536/ihj.22-129. Epub 2022 Jul 14. PubMed 35831157 ↗
  • Holmqvist F, Guan N, Zhu Z, Kowey PR, Allen LA, Fonarow GC, Hylek EM, Mahaffey KW, Freeman JV, Chang P, Holmes DN, Peterson ED, Piccini JP, Gersh BJ; ORBIT-AF Investigators. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2015 May;169(5):647-654.e2. doi: 10.1016/j.ahj.2014.12.024. Epub 2015 Feb 7. PubMed 25965712 ↗
  • Deng F, Raza A, Guo J. Treating obstructive sleep apnea with continuous positive airway pressure reduces risk of recurrent atrial fibrillation after catheter ablation: a meta-analysis. Sleep Med. 2018 Jun;46:5-11. doi: 10.1016/j.sleep.2018.02.013. Epub 2018 Mar 22. PubMed 29773211 ↗
  • de Heide J, Kock-Cordeiro DBM, Bhagwandien RE, Hoogendijk MG, van der Meer KC, Wijchers SA, Szili-Torok T, Zijlstra F, Lenzen MJ, Yap SC. Impact of undiagnosed obstructive sleep apnea on atrial fibrillation recurrence following catheter ablation (OSA-AF study). Int J Cardiol Heart Vasc. 2022 Mar 24;40:101014. doi: 10.1016/j.ijcha.2022.101014. eCollection 2022 Jun. PubMed 35663451 ↗
  • Minami T, Yoshizawa T, Murase K, Komasa A, Aizawa T, Yamagami S, Tanaka M, Shizuta S, Sato S, Ono K, Hirai T, Kimura T, Chin K. Associations Among Sleep Apnea, Objective or Subjective Sleep Duration, and Recurrence of Atrial Fibrillation in Patients Who Undergo Radiofrequency Catheter Ablation for Persistent Atrial Fibrillation - A Prospective Observational Study. Circ J. 2025 Jan 24;89(2):184-194. doi: 10.1253/circj.CJ-24-0537. Epub 2024 Nov 12. PubMed 39537150 ↗
  • Yeghiazarians Y, Jneid H, Tietjens JR, Redline S, Brown DL, El-Sherif N, Mehra R, Bozkurt B, Ndumele CE, Somers VK. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021 Jul 20;144(3):e56-e67. doi: 10.1161/CIR.0000000000000988. Epub 2021 Jun 21. PubMed 34148375 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2029, 32 months after the start.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 32 months is close to that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 2, 2026
StartActual
May 12, 2026
Primary completionEst.
Jan 31, 2029
CompletionEst.
Jan 31, 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Shijiazhuang Great Wall Hospital of Integrated Traditional Chinese and Western Medicine · Shijiazhuang, ChinaNot yet recruiting→Recruiting
  • The Ninth Hospital of Xingtai · Xingtai, ChinaNot yet recruiting→Recruiting
Show 3 added (3 China)
  • Shangqiu First People's Hospital · Shangqiu, China
  • Yan'an Hospital of Kunming City · Kunming, China
  • Tianjin Medical University Second Hospital · Tianjin, China
Oct 5, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedPatients with persistent AF scheduled for first-timewho received catheter ablation for the first time.
Oct 5, 2026
Site contacts
Changed at 8 sites. See the sites
Show 8 sites
  • Peking University International Hospital · Beijing, ChinaContact c•••@pkuih.edu.cn · •••6163→j•••@pkuih.edu.cn · •••6163Contact person changed (no phone or email listed)
  • Zhangzhou Hospital of Fujian Province · Zhangzhou, ChinaContact 3•••@qq.com · •••2000→l•••@163.com · •••2000Contact person changed (no phone or email listed)
  • The Ninth Hospital of Xingtai · Xingtai, ChinaContact j•••@126.com · •••1827→l•••@sina.com · •••1827Contact person changed (no phone or email listed)
  • Second Affiliated Hospital of Harbin Medical University · Harbin, ChinaContact z•••@163.com · •••6870→m•••@163.com · •••6870Contact person changed (no phone or email listed)
  • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, ChinaContact o•••@163.com · •••3114→d•••@163.com · •••3114Contact person changed (no phone or email listed)
  • Wuhan No. 1 Hospital · Wuhan, ChinaContact x•••@163.com · •••2144→w•••@163.com · •••2144Contact person changed (no phone or email listed)
  • Shengli Oilfield Central Hospital · Dongying, ChinaContact h•••@163.com · •••1222→z•••@126.com · •••1222Contact person changed (no phone or email listed)
  • Tianjin Chest Hospital · Tianjin, ChinaContact z•••@163.com · •••5111→z•••@163.com · •••5111Contact person changed (no phone or email listed)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    3 sites added. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Shijiazhuang Great Wall Hospital of Integrated Traditional Chinese and Western Medicine · Shijiazhuang, ChinaNot yet recruiting→Recruiting
    • The Ninth Hospital of Xingtai · Xingtai, ChinaNot yet recruiting→Recruiting
    Show 3 added (3 China)
    • Shangqiu First People's Hospital · Shangqiu, China
    • Yan'an Hospital of Kunming City · Kunming, China
    • Tianjin Medical University Second Hospital · Tianjin, China
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatients with persistent AF scheduled for first-timewho received catheter ablation for the first time.
    Site contacts Changed at 8 sites. See the sites
    Show 8 sites
    • Peking University International Hospital · Beijing, ChinaContact c•••@pkuih.edu.cn · •••6163→j•••@pkuih.edu.cn · •••6163Contact person changed (no phone or email listed)
    • Zhangzhou Hospital of Fujian Province · Zhangzhou, ChinaContact 3•••@qq.com · •••2000→l•••@163.com · •••2000Contact person changed (no phone or email listed)
    • The Ninth Hospital of Xingtai · Xingtai, ChinaContact j•••@126.com · •••1827→l•••@sina.com · •••1827Contact person changed (no phone or email listed)
    • Second Affiliated Hospital of Harbin Medical University · Harbin, ChinaContact z•••@163.com · •••6870→m•••@163.com · •••6870Contact person changed (no phone or email listed)
    • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, ChinaContact o•••@163.com · •••3114→d•••@163.com · •••3114Contact person changed (no phone or email listed)
    • Wuhan No. 1 Hospital · Wuhan, ChinaContact x•••@163.com · •••2144→w•••@163.com · •••2144Contact person changed (no phone or email listed)
    • Shengli Oilfield Central Hospital · Dongying, ChinaContact h•••@163.com · •••1222→z•••@126.com · •••1222Contact person changed (no phone or email listed)
    • Tianjin Chest Hospital · Tianjin, ChinaContact z•••@163.com · •••5111→z•••@163.com · •••5111Contact person changed (no phone or email listed)
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07444372
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
May 12, 2026
Primary completion
Jan 31, 2029 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Jiang Xie, Professor
Contact
frank782008@aliyun.com
+86 64456360

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion